Steven Armen Boyd

USPTO Granted Patents = 51 (Patent Applications = 14)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 9)

Average Co-Inventor Count = 8.6

ph-index = 11

Forward Citations = 607(Granted Patents)

Forward Citations (Not Self Cited) = 584(Oct 12, 2025)

Location History:

Palatine, IL (US) (1993)
Mundelein, IL (US) (1993 - 2008)
Pittsburgh, PA (US) (2014)
Longmont, CO (US) (2007 - 2015)
Boulder, CO (US) (2011 - 2015)
Mars, PA (US) (2015 - 2022)
Chester Springs, PA (US) (2019 - 2024)

Company Filing History:

18 out of 4,177

Abbott Laboratories Corporation

Venatorx Pharmaceuticals, Inc.

patents

4. 3 out of 27

Knopp Biosciences, LLC

Takeda Pharmaceutical Company Limited

patents

7. 1 out of 4,442

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 1993-2024

Loading Chart...

51 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12173018 - Penicillin-binding protein inhibitors (2024-12-24),

2. 12102648 - Orally-bioavailable nucleoside analogs (2024-10-01),

3. 12084445 - Broad-spectrum carbapenems (2024-09-10),

4. 11638715 - Orally-bioavailable nucleoside analogs (2023-05-02),

5. 11566001 - Hepatitis B capsid assembly modulators (2023-01-31),

6. 11332485 - Penicillin-binding protein inhibitors (2022-05-17),

7. 11267826 - Penicillin-binding protein inhibitors (2022-03-08),

8. 11247965 - Hepatitis B capsid assembly modulators (2022-02-15),

9. 11046716 - Beta-lactamase inhibitors (2021-06-29),

10. 11014881 - Hepatitis B capsid assembly modulators (2021-05-25),

11. 10590076 - Hepatitis B capsid assembly modulators (2020-03-17),

12. 10464952 - Beta-lactamase inhibitors (2019-11-05),

13. 10399996 - Beta-lactamase inhibitors (2019-09-03),

14. 9914708 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2018-03-13),

15. 9650376 - [object Object] (2017-05-16),

Title: The Innovative Contributions of Steven Armen Boyd

Introduction

Steven Armen Boyd, a prolific inventor based in Longmont, Colorado, holds an impressive portfolio of 48 patents. His work primarily focuses on significant advancements in the pharmaceutical sector, revolutionizing treatments for various viral infections. Notably, Boyd's contributions reflect his dedication to addressing critical health challenges.

Latest Patents

Among his most recent innovations are two noteworthy patents. The first patent centers on "Orally-bioavailable nucleoside analogs," which includes pharmaceutical compositions useful for treating coronavirus infections, including SARS-CoV-2. This development holds promise in the ongoing fight against viral pandemics. The second patent involves "Hepatitis B capsid assembly modulators," which describes novel compounds and compositions aimed at the treatment of hepatitis B. Both patents underscore Boyd's commitment to enhancing public health through innovative pharmaceutical solutions.

Career Highlights

Steven Boyd's professional journey includes significant tenures at renowned companies like Abbott Laboratories Corporation and Array Biopharma Inc. These affiliations have provided him with a platform to innovate and contribute to advancements in medical science, emphasizing his expertise in pharmaceutical research.

Collaborations

Throughout his career, Boyd has collaborated with talented individuals in the field, including Martin Winn and Kevin Ronald Condroski. These collaborations have facilitated the exchange of ideas and fostered innovation, further amplifying the impact of his work in the industry.

Conclusion

Steven Armen Boyd's contributions to the field of pharmaceuticals through his 48 patents highlight his role as a leading inventor. His focus on developing treatments for urgent health issues demonstrates the importance of innovation in medicine. With his ongoing efforts, Boyd continues to inspire future generations of inventors and researchers striving to make a difference in healthcare.

This text is generated by artificial intelligence and may not be accurate.